Literature DB >> 14586548

Androgens and prostate cancer.

Alan I So1, Antonio Hurtado-Coll, Martin E Gleave.   

Abstract

Over 60 years ago Huggins and Hodges demonstrated the importance of androgens and prostate cancer. Since then, significant research has revealed that this relationship is multi-faceted and is interwoven with different signaling cascades and protein coactivators. The complex interrelationship between hormone and cancer is best exemplified by the recurrence and progression of prostate cancer after hormonal therapy to a lethally resistant phenotype despite initially encouraging therapeutic responses. If we are to significantly improve survival with novel therapies, further understanding of the emergence of this resistant phenotype is essential. The purpose of this article is to review the mechanisms of androgen action and its relation to hormonal therapy and mechanisms of hormonal resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586548     DOI: 10.1007/s00345-003-0373-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  99 in total

1.  A brief history of testosterone.

Authors:  E R Freeman; D A Bloom; E J McGuire
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

Review 2.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

3.  The testis and tissue transplantation: historical aspects.

Authors:  B P Setchell
Journal:  J Reprod Immunol       Date:  1990-08       Impact factor: 4.054

4.  Her-2-neu expression and progression toward androgen independence in human prostate cancer.

Authors:  S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

5.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

Authors:  N Bruchovsky; J D Wilson
Journal:  J Biol Chem       Date:  1968-04-25       Impact factor: 5.157

Review 6.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

7.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas.

Authors:  A Wellmann; C Thieblemont; S Pittaluga; A Sakai; E S Jaffe; P Siebert; M Raffeld
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Authors:  R S D Brown; J Edwards; A Dogan; H Payne; S J Harland; J M S Bartlett; J R W Masters
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

Review 9.  Clusterin: physiologic and pathophysiologic considerations.

Authors:  M E Rosenberg; J Silkensen
Journal:  Int J Biochem Cell Biol       Date:  1995-07       Impact factor: 5.085

10.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12
View more
  9 in total

1.  Does prolactin induce apoptosis? Evidences in a prostate cancer in vitro model.

Authors:  D Giuffrida; A Perdichizzi; M C Giuffrida; S La Vignera; R D'Agata; E Vicari; A E Calogero
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

2.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

3.  Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo.

Authors:  Thomas T Y Wang; Tamaro S Hudson; Tien-Chung Wang; Connie M Remsberg; Neal M Davies; Yoko Takahashi; Young S Kim; Harold Seifried; Bryan T Vinyard; Susan N Perkins; Stephen D Hursting
Journal:  Carcinogenesis       Date:  2008-06-26       Impact factor: 4.944

4.  Behavioral stress accelerates prostate cancer development in mice.

Authors:  Sazzad Hassan; Yelena Karpova; Daniele Baiz; Dana Yancey; Ashok Pullikuth; Anabel Flores; Thomas Register; J Mark Cline; Ralph D'Agostino; Nika Danial; Sandeep Robert Datta; George Kulik
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

5.  Bioglycans and natural glycosides as a promising research topic in bioorganic chemistriy.

Authors:  Yu S Ovodov
Journal:  Acta Naturae       Date:  2010-07       Impact factor: 1.845

Review 6.  Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?

Authors:  Nancy E Moran; Jennifer M Thomas-Ahner; Lei Wan; Krystle E Zuniga; John W Erdman; Steven K Clinton
Journal:  J Nutr       Date:  2022-06-09       Impact factor: 4.687

Review 7.  Role of miRNA let-7 and its major targets in prostate cancer.

Authors:  Siegfried Wagner; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

8.  5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.

Authors:  Alexander B Opoku-Acheampong; Jamie N Henningson; Amanda P Beck; Brian L Lindshield
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

9.  Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.

Authors:  Kathrine Røe; Åse Bratland; Ljiljana Vlatkovic; Harald Bull Ragnum; Marie Grøn Saelen; Dag Rune Olsen; Laure Marignol; Anne Hansen Ree
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.